Dexmedetomidine for Less Invasive Surfactant Administration: A Pilot Study.

Area of Science:

• Neonatal Medicine
• Pediatric Pharmacology
• Respiratory Care

Background:

• Less invasive surfactant administration (LISA) is a preferred method for surfactant delivery in neonates.
• The role of pre-LISA sedation in optimizing outcomes remains under investigation.

Purpose of the Study:

• To evaluate the safety and efficacy of dexmedetomidine as a sedative agent prior to LISA in preterm and early-term infants.
• To compare outcomes based on post-menstrual age (PMA) at birth.

Main Methods:

• Retrospective analysis of 37 preterm and early-term infants receiving intravenous dexmedetomidine for LISA.
• Assessment of primary outcomes including absence of bradycardia, hypotension, hypothermia, respiratory depression, and LISA success (no intubation within 72 hours).
• Comparison of infants based on a 32-week PMA cutoff.

Main Results:

• The overall success rate for LISA was 89.2%.
• Mild hypothermia (16.2%) and apnea/bradycardia (27%) were observed within 24 hours.
• Infants born before 32 weeks received significantly lower dexmedetomidine doses (p < 0.01).
• Safety and success rates were comparable between PMA groups.

Conclusions:

• Dexmedetomidine is a feasible pre-LISA sedation option for neonates.
• Efficacy and safety of dexmedetomidine for LISA are not significantly affected by PMA.
• Findings support further research into dexmedetomidine for LISA sedation protocols.